Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or primary open-angle glaucoma. Subjects will be followed for 2 weeks.

Inclusion Criteria:

• Ocular hypertension or primary open-angle glaucoma
• Females of non-childbearing potential
• Subject requires IOP-lowering therapy in both eyes
• IOP ≥ 22 mm Hg and ≤ 34 mm Hg
• Has a visual acuity score of 20/100 or better in each eye

Exclusion Criteria:

• Uncontrolled systemic disease
• Active ocular disease
• Alteration of existing chronic systemic medications
• Known allergy or sensitivity to the study medications
• Ophthalmic corticosteroids
• Visual field loss which in the opinion of the investigator is functionally significant
• History of ocular laser, intraocular surgery, or refractive surgery